Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LEI-106
Cat. No.:
OB0425LY-085
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
LEI-106 is a dual sn-1-Diacylglycerol lipase α (DAGL-α)/ABHD6 inhibitor.
Synonyms:
1620582-23-1; 2-[(2,2-Dimethyl-3,4-dihydrochromen-6-yl)sulfonyl-[(4-phenoxyphenyl)methyl]amino]acetic acid; N-((2,2-Dimethylchroman-6-yl)sulfonyl)-N-(4-phenoxybenzyl)glycine
CAS No.:
1620582-23-1
Compound CID:
102340761
Formula:
C26H27NO6S
Formula Weight:
481.56
Specification
Target:
MAGL; DAGL
Pathway:
Metabolic enzyme/Protease
Storage:
Storage at -20°C.
Applications:
LEI-106 can be used to inhibit the hydrolysis of [14C]-sn-1-oleoyl-2-arachidonoyl-glycerol.
